Full-Time

Director – Competitive Intelligence

Confirmed live in the last 24 hours

Revolution Medicines

Revolution Medicines

201-500 employees

Develops targeted therapies for RAS-driven cancers

Biotechnology
Healthcare

Compensation Overview

$210k - $253kAnnually

Senior

San Carlos, CA, USA

Position is based at headquarters in Redwood City, CA.

Category
Business Research
Strategy Development
Business & Strategy
Required Skills
Market Research
Data Analysis
Requirements
  • Minimum of 5 years' experience in competitive intelligence, market research, or a related field within the pharmaceutical and/or biotechnology industry
  • Demonstrated leadership, influencing skills, creativity, problem solving and ability to manage complexity
  • Experience in new product launches and pre-launch environments.
  • Track record of being a collaborative team player, and adaptive to meet the needs of a growing business
  • Excellent organizational skills and an ability to prioritize effectively to deliver results within reasonably established timelines.
  • Ability to represent Revolution Medicines well: strong interpersonal skills including verbal and written communication.
  • Entrepreneurial mindset, with a tolerance for ambiguity, and a passion for helping cancer patients
  • Advanced degree (PhD, Master’s) preferred
  • 8+ years of experience in competitive intelligence with focus in Oncology
  • Demonstrated ability to synthesize complex information and influence decision-making at the executive level.
Responsibilities
  • Conduct thorough competitive and market assessments to identify market dynamics, trends, and potential impacts on Revolution Medicines’ pipeline, delivering insights to key stakeholders
  • Collaborate with stakeholders across the company (including Commercial, Medical Affairs, and R&D) to integrate internal and external information, analytics, and data
  • Coordinate and execute coverage of key medical congresses; outputs may include daily and post-conference summaries and post-conference summary presentations
  • Maintain an in-depth understanding of Revolution Medicines’ diverse product offerings, competitive positioning, and the broader market dynamics shaping the industry's future.
  • Benchmark competitor clinical data, business models and capabilities to develop insights and recommendations that will help inform and refine Revolution Medicines’ strategy
  • Proactively facilitate the identification and prioritization of intelligence efforts critical to strategic planning and execution for key stakeholders and will provide direction for the design and refinement of intelligence plans.

Revolution Medicines develops treatments specifically for cancers caused by RAS gene mutations, which are common in difficult-to-treat cancers like pancreatic, colorectal, and lung cancers. Their main product line includes RASON Inhibitors, designed to target and inhibit RAS proteins that contribute to cancer growth. The company uses a Tri Complex Inhibitor platform to create these specialized therapies. Unlike many competitors, Revolution Medicines focuses solely on RAS-driven cancers, allowing them to carve out a niche in the oncology market. Their goal is to transform cancer treatment by providing effective targeted therapies for patients suffering from these challenging conditions.

Company Stage

IPO

Total Funding

$219.8M

Headquarters

Redwood City, California

Founded

2014

Growth & Insights
Headcount

6 month growth

15%

1 year growth

42%

2 year growth

137%
Simplify Jobs

Simplify's Take

What believers are saying

  • The acquisition of EQRx is expected to add over $1 billion in net cash, significantly bolstering Revolution Medicines' financial position.
  • Successful public offerings and underwriters' full exercise of options have brought substantial capital, indicating strong investor confidence.
  • The company's innovative RASON Inhibitors and Tri Complex Inhibitor platform have the potential to revolutionize treatment for RAS-driven cancers, offering significant clinical impact.

What critics are saying

  • The highly specialized focus on RAS-driven cancers may limit market size and revenue potential compared to broader oncology companies.
  • Integration challenges from the acquisition of EQRx could divert focus and resources, potentially impacting ongoing projects.

What makes Revolution Medicines unique

  • Revolution Medicines focuses exclusively on RAS-driven cancers, a niche but critical area in oncology, unlike broader-spectrum oncology companies.
  • Their Tri Complex Inhibitor platform allows for highly specialized treatments, setting them apart from competitors with more generalized approaches.
  • The company's revenue model, which includes licensing, co-development partnerships, and direct sales, provides multiple revenue streams, enhancing financial stability.

Help us improve and share your feedback! Did you find this helpful?